HURA

Congress Trades

Name	Value	Action	Amount Range	Price	Last Price
Laurel LeeRepublican $75k BuyJul 13, 2025 $50k-$100k -- $2.34
Laurel LeeRepublican $8.0k BuyNov 25, 2024 $1k-$15k -- $2.34
Laurel LeeRepublican $175k OtherOct 18, 2024 $100k-$250k -- $2.34

News

prnewswire.comTuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Updateprnewswire.comMay 15

prnewswire.comTuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conferenceprnewswire.comMay 12

prnewswire.comTuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028prnewswire.comApr 22

prnewswire.comTuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operationsprnewswire.comApr 7

prnewswire.comTuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Updateprnewswire.comApr 1

Trade HURA

About TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.

CEO: James A. Bianco
IPO Date: Feb 22, 2013

Market Data

Open: $2.05
High: $2.12
Low: $1.95
Volume: 390.9K
52W High: $3.90
52W Low: $0.41

Valuation

Market Cap: $129M
Enterprise Value: $123M

Financials

Free Cash Flow: $-28M
Revenue: $0
Net Income: $-30M
Cash: $3.6M
Debt: $503k

Events

EarningsAug 13

EPS est. -0.15333